Fennec Pharmaceuticals Inc. (TSX:FRX)
9.57
+0.09 (0.95%)
Mar 21, 2025, 3:50 PM EST
Fennec Pharmaceuticals Revenue
In the year 2024, Fennec Pharmaceuticals had annual revenue of $47.54M USD with 123.69% growth. Fennec Pharmaceuticals had revenue of $7.93M in the quarter ending December 31, 2024, a decrease of -18.59%.
Revenue
$47.54M
Revenue Growth
+123.69%
P/S Ratio
n/a
Revenue / Employee
$1.64M
Employees
29
Market Cap
256.27M CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Green Thumb Industries | 1.64B |
dentalcorp Holdings | 1.55B |
Sienna Senior Living | 893.16M |
WELL Health Technologies | 957.69M |
Extendicare | 1.47B |
Curaleaf Holdings | 1.93B |
Trulieve Cannabis | 1.71B |
Cronos Group | 169.23M |
Fennec Pharmaceuticals News
- 18 days ago - Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Fennec Pharmaceuticals GAAP EPS of -$0.06, revenue of $7.93M - Seeking Alpha
- 18 days ago - Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 19 days ago - Earnings Scheduled For March 10, 2025 - Benzinga
- 22 days ago - Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 - GlobeNewsWire
- 7 weeks ago - Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany - GlobeNewsWire
- 7 weeks ago - Insider Sell Alert: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
- 3 months ago - Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - GlobeNewsWire